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1. Introduction  
Although type 2 diabetes mellitus (T2DM) is pandemic globally, Asia-Pacific has the largest 
diabetes burden in the world (International Diabetes Federation, 2009). This region is home 
to more than half of the world's population with some of the richest and most developed 
countries alongside many developing as well as a significant number of poorest and least 
developed ones. Despite existing knowledge and recent progress in therapy, the majority of 
diabetic patients do not achieve an optimal blood glucose control. With a predisposition to 
disproportionate effect on the lower socioeconomic groups, the combination with the 
resulting poor health consequences, disability, and dependency is of concern (L.E. Egede, 
2004). Taken together with the confluence of the recent upsurge of obesity and an ageing 
population, this will have far-reaching implications in terms of income security, social 
welfare and medical services (J.C. Chan et al., 2009; C. Pan et al., 2010). The consequent 
enormous health, social and economic burden will overwhelm the social and health care 
systems, particularly of the low and middle-income developing countries in the Asia-Pacific 
(D.O. Abegunde et al., 2007).   
Controlling this disease is important for reducing complications, improving quality of life, 
and reducing the economic burden associated with disability and dependency (UKPDS 37, 
1999). Strategies for the effective treatment of this devastating disease are of great interest to 
the general public, government organisations, and the healthcare industry. Besides 
nutritional intervention as an essential component of diabetes management, botanicals and 
associated products are also remedies for T2DM in traditional medicine practices. In the past 
decade, enhanced global research into botanicals has identified more than 600 plants as 
potential contributors to the management of T2DM (M. Modak et al., 2007; L.W. Qi et al., 
2010).  
Use of plant-based complementary and alternative medicine is common in many 
communities (H.Y. Chang et al., 2007; A. Metcalfe et al., 2010; H.T. Nguyen et al., 2010). In 
the past, the traditional ‘observation’ as remedies in complimentary alternative medicines, 
preliminary preclinical studies, and anecdotal evidence, have endorsed the use of these 
plants. However, their safety and efficacy in humans are of concern. Adding to the 
complexity of such issues are the challenges in the management of T2DM. Specifically, these 
are the use of pluralistic medical practices and the relevant roles of these botanicals in the 
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management of T2DM in mainstream medicine (C.C. Shih et al., 2010). In addition, there are 
also issues of adequate regulatory standards and patients’ disclosures to their mainstream 
medical practitioners (S. Tyreman, 2010). Thus, rigorous research in translating these 
botanicals to the clinical arena is warranted (M. Kantor, 2009).  
There has been no evaluation of the clinical trials for the use of these emerging botanicals for 
type 2 diabetes mellitus. The aim of this review is to assess the effects of botanicals on type 2 
diabetes mellitus. Existing opportunity for these botanicals in the management of diabetes 
and the state of the evidence for their anti-diabetic usefulness will be discussed. This 
includes issues pertaining to these clinical trials, the quality of antihyperglycemic efficacy 
data and related complementary metabolic effects. The adverse effects of interventions, a 
critical aspect of diabetic care, will also be emphasised. Finally, important limitations, which 
may affect the interpretation of data from these clinical studies and the implications for 
future research; in the context of T2DM in developing Asia-Pacific countries, will also be 
addressed.  
2. Research methodology  
2.1 Methods  
Search was carried out in the following databases: MEDLINE, CINHAL, Proquest Health & 
Medical Complete, ProQuest Dissertations & Theses, CAM-PubMed, and the Cochrane 
Library Database from April 2006 to March 2011 using the MeSH terms CAM, alternative 
therapies, hypoglycemic plants or botanicals, anti-diabetic plants or botanicals and individual 
botanicals and supplement names from popular sources, each crossed with the term diabetes 
mellitus. Databases of ongoing trials (http://www.controlled-trials.com/ with links to 
several databases and https://www.clinicaltrialsregister.eu/) were also searched. 
Only emerging botanical derived products or drugs not in the established armamentarium 
of modalities used in the current management of T2DM were included. Supplements in 
which animal products were major components were excluded. We also did not include 
soluble or dietary fibre supplements that were already established in conventional diabetes 
nutrition advice.  
Specific filters for retrieving controlled clinical trial, double-blind, placebo-controlled, phase 
II, or III randomised controlled trials of any duration; published systematic reviews and 
meta-analyses of randomised controlled trials; and randomised controlled trials (RCT) in 
human adults (aged ≥18), were incorporated. Hand searching was not performed, but 
reference lists of identified systematic reviews, meta-analyses, and pooled analyses were 
reviewed to identify further studies. Unpublished studies were also not sought. References 
in any articles that met the inclusion criteria were included. There were no language 
restrictions. 
2.1.1 Studies selection  
The results of the search from the various databases were entered in a bibliographic 
manager software, Endnote X4 (Thomson Reuters). Duplicates were automatically 
discarded. We screened the identified articles to ensure they met pre-determined inclusion 
criteria. To ensure uniformity of appraisal for each study a checklist of specified inclusion 
criteria was used. The initial review for all identified citations included titles or abstracts, or 
both. Following, a second review stage of full text publications for citations remaining after 
the first pass was carried out. We used a positive exclusion method to exclude only those 
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publications that did not meet one or more of the inclusion criteria. In ambiguous cases, 
inclusion of studies was based on expert opinion.   
2.1.2 Data extraction  
A structured table was developed for data extraction to ensure uniformity of appraisal for 
each study as well as capturing all relevant data. Extracted data consisted of study 
characteristics (such as treatments and doses, status of T2DM and associated conditions, 
duration, and study location) and relevant outcomes (glycaemic control, adverse effects, 
morbidity, blood lipids level, body weight or body mass index).  
2.1.3 Outcome measures 
There were two primary outcomes: glycaemic control and adverse effects. These were 
considered as measures of efficacy and measures of tolerability respectively.  Secondary 
outcomes were included when present. These included serum insulin, body weight or body 
mass index, blood lipids level and morbidity. Morbidity included both type 2 diabetes 
mellitus as well as cardiovascular-related comorbidity and all cause morbidity. The above 
data were only extracted and analysed when reported.  
Data for glycaemic control, FBG and 2HPBG, was collected for trials of at least 6 weeks and 
over. For HbAic, trials over three months were considered. Data of all other outcomes will 
be collected from studies of any duration.  
2.1.4 Statistical analysis 
Analyses were performed on data that were explicitly reported in the individual papers, 
with no imputations for data that were not reported. When available, we analysed the 
intention-to-treat population; when this was not possible, we used data from the last 
observation carried forward. The analyses were conducted using RevMan 5.0 meta-analytic 
software (The Cochrane Collaboration, 2008).  
2.2 Results  
The search returned a total of 45 publications and abstracts (Figure 1). After review of titles 
and abstracts, we identified and included 22 relevant papers. All were clinical trials (1 
clinical trial, 1 controlled clinical trial, and 20 randomised controlled trials) (Table 1). Six 
were excluded because duration of these studies were less than 6 weeks. Another was 
excluded because the primary outcome was not glycaemic control or adverse effects. Of the 
15 remaining studies, all were randomised controlled trials. All the trials consisted of 
different plant-based interventions.  
2.2.1 Characteristics of included studies 
There were fifteen studies that met all the inclusion criteria. Table 1 shows the characteristics 
of the trials. The study participants for each trial range from 24 to 109. All studies included 
both genders. The participants were middle-age and older adults. Study length ranged from 
12 weeks to 4 months.  
Four papers provided information on different forms of cinnamon extracts (S.M. Blevins et 
al., 2007; P. Crawford, 2009; B. Mang et al., 2006; S. Suppapitiporn& N. Kanpaksi, 2006). Two 
papers provided information on different forms of Silybum marianum preparations (H.F. 
Huseini et al., 2006; S.A. Hussain, 2007) and another two papers provided findings of 
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Fig. 1. Modified PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses ) flow-chart of study selection (D. Moher et al., 2009) 
catechin-containing tea preparations (T. Mackenzie et al., 2007; T. Nagao et al., 2009). The 
rest of the seven papers were focussed on 7 diffent plant-based preparations for T2DM 
(A.M. Dans et al., 2007; H.F. Huseini et al., 2009; V.T. Huyen et al., 2010; R. Kuriyan et al., 
2008; F.R. Lu et al., 2008; V. Vuksan et al., 2008; S. Zibadi et al., 2008).   
2.2.2 Risks of bias  
Risk of bias assessments included assessments of minimisation of selection, performance, 
attrition, reporting biases as well as other sources of biases (A.R. Jadad et al., 1996; L.L. 
Kjaergard et al., 2001; K.F. Schulz et al., 1995).  
One trial was a crossover randomised trial (V. Vuksan et al., 2008), while the rest was 
parallel-group design. Recruitment of patients was limited to the centres of the studies. Of 
the 15 included randomised trials, five trials described the methods of randomisation (P. 
Crawford, 2009; A.M. Dans et al., 2007; H.F. Huseini et al., 2006; T. Mackenzie et al., 2007; V. 
Vuksan et al., 2008). Among them, three used simple randomisation methods (random 
number generator, table and computer generated sequence) (A.M. Dans et al., 2007; T. 
Mackenzie et al., 2007; V. Vuksan et al., 2008), one used block randomisation technique (P. 
Crawford, 2009) and another used a balanced randomisation technique (H.F. Huseini et al., 
2006). Only three trials reported generation of allocation concealment (P. Crawford, 2009; 
A.M. Dans et al., 2007; H.F. Huseini et al., 2006). The rest of the trials did not document 
adequate methods of randomisation.  
Records identified through 
database searching 
(n = 83)
Additional records identified 
through other sources 
(n = 8)
Records identified after review of titles and 
abstracts as well as removal of  duplicates 
removed (n = 45)
Records excluded 
(n = 23)
Full-text articles assessed 
for eligibility 
(n = 22)
Full-text articles excluded, 
with reasons 
(n = 7)
Studies included in review 
(n = 15)
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Ref Study design Subjects Intervention Control 
(S.M. Blevins et al., 
2007) 
DBRPCT 58 with T2DM 
Cinnamon 
powder capsule 
(C. cassia) 
Wheat flour 
placebo capsule 
(B. Mang et al., 
2006) 
DBRPCT 65 with T2DM 
Aqueous 
cinnamon extract 
(C. cassia) capsule
Microcrystalline 
cellulose placebo 
capsule 
(S. Suppapitiporn& 
N. Kanpaksi, 2006)
SBRPCT 60 with T2DM 
Cinnamon 
powder capsule 
(C. Cassia) 
Placebo 
(P. Crawford, 2009) RCT 109 with T2DM 
Cinnamon 
capsule (C. Cassia)
No placebo 
intervention 
(A.M. Dans et al., 
2007) 
DBRPCT 
40 with T2DM 
 
Momordica 
charantia leaf 
capsules 
Placebo 
(H.F. Huseini et al., 
2009) 
DBRPCT 50 with T2DM 
Citrullus. 
colocynthis dried 
fruit powder 
capsules 
Placebo 
(H.F. Huseini et al., 
2006) 
DBRPCT 51 with T2DM 
Silybum marianum 
seed extract 
tablets 
Placebo 
(S.A. Hussain, 
2007) 
DBRPCT 59 with T2DM 
Silybum marianum
extract tablets 
Placebo 
(V.T. Huyen et al., 
2010) 
DBRPCT 24 with T2DM 
Gynostemma 
pentaphyllum tea
Placebo tea 
(R. Kuriyan et al., 
2008) 
DBRPCT 60 with T2DM 
Coccinia cordifolia 
leaves and fruit 
extract capsules
Maltosedextrin 
capsule placebo 
(F.R. Lu et al., 
2008) 
RCT 69 with T2DM 
Trigonella foenum-
graecum powder 
capsules 
Chinese yam 
powder placebo 
(T. Mackenzie et 
al., 2007) 
DBRPCT 49 with T2DM 
Green and black 
tea extract 
capsules 
Cellulose capsule 
placebo 
(T. Nagao et al., 
2009) 
RCT 43 with T2DM 
Green tea extract 
(catechin-rich 528 
mg) beverage 
Low dose 
catechin (96.3 mg) 
placebo tea 
(V. Vuksan et al., 
2008) 
DBRPCT, 
crossover 
19 with T2DM 
Panax ginseng 
extract capsules
Vanilla flavoured 
cornstarch 
capsule placebo 
(S. Zibadi et al., 
2008) 
RCT 48 with T2DM 
Pinus maritima 
bark extract pill 
Placebo 
Table 1. Clinical trials of botanical interventions for type 2 diabetes mellitus.   
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Blinding of all patients, trials investigators  and assessors were reported in five trials (A.M. 
Dans et al., 2007; H.F. Huseini et al., 2009; H.F. Huseini et al., 2006; S.A. Hussain, 2007; T. 
Mackenzie et al., 2007). Eight trials did not report any aspects of blinding at all (V.T. Huyen 
et al., 2010; A. Khan et al., 2003; R. Kuriyan et al., 2008; F.R. Lu et al., 2008; B. Mang et al., 
2006; T. Nagao et al., 2009; S. Suppapitiporn& N. Kanpaksi, 2006; V. Vuksan et al., 2008). 
While the rest documented blinding of patients and trial investigators (S.M. Blevins et al., 
2007) or assessors only (P. Crawford, 2009; S. Zibadi et al., 2008). Both dropouts of patients 
and intention-to-treat analysis were reported in five trials (S.M. Blevins et al., 2007; P. 
Crawford, 2009; A.M. Dans et al., 2007; F.R. Lu et al., 2008; S. Zibadi et al., 2008). One trial 
reported only dropouts of patients but not intention-to-treat analysis (H.F. Huseini et al., 
2006).  
Four papers did not mention appropriate inclusion, exclusion criteria or both (P. Crawford, 
2009; R. Kuriyan et al., 2008; B. Mang et al., 2006; V. Vuksan et al., 2008). A statement of 
power calculation had been undertaken or give any justification for the numbers of 
participants needed to detect an effect of differences with intervention was documented in 
five papers (S.M. Blevins et al., 2007; P. Crawford, 2009; A.M. Dans et al., 2007; T. Mackenzie 
et al., 2007; V. Vuksan et al., 2008). Potential confounding factors were not elaborated in four 
papers (S.M. Blevins et al., 2007; P. Crawford, 2009; H.F. Huseini et al., 2009; B. Mang et al., 
2006). There was also no uniform tool to assess adjunct dietary management in all these 
trials.  
2.2.3 Effects of interventions 
In view of the quality of data and variability of treatment, meta-analysis was not performed. 
One trial compared single botanical preparation without adjunct oral hypoglycaemics with 
placebo. The rest of the trials compared the botanical preparation with adjunct oral 
hypoglycaemicis with placebo. These tested botanicals included preparations of Cinnamon 
cassia, Momordica charantia, Citrullus Colocynthis, Silybum marianum, Gynostemma 
pentaphyllum, Coccinia cordifolia, trigonella foenum-graecum L, Camelia sinesis (tea) and Pinus 
maritima. Among them, Cinnamon cassia was tested in 4 trials, while Silybum marianum and 
Camelia sinesis (tea) were each tested in two trials. The reported outcomes included fasting 
blood glucose, postprandial blood glucose, HbA1c, fasting serum insulin levels, serum 
lipids level, symptoms, and adverse effects. 
Single botanical preparations versus placebo 
Compared with placebo (maltodextrin capsules), Coccinia cordifolia showed significantly 
better effect on normalisation of fasting blood glucose. There was a mean decrease of 15.6% 
in the intervention group compared to mean increase of 6% in the placebo group. Similarly, 
with the 2 hour postprandial blood glucose, there was a significant mean decrease of 18.5% 
in the intervention group. No significant change was noted in the placebo control group. 
There was also significant decrease in the glycosylated haemoglobin level in the 
intervention group.  
Mild hypoglycaemic symptoms, perspiration, excessive hunger and slight dizziness, was 
noted post-prandially in 59% of the participants in the intervention group. However, there 
was no significant difference in minor gastrointestinal adverse effects between the two 
groups.  
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Single botanical preparations with oral hypoglycaemic agent (OHA) adjuncts versus 
placebo 
The effect of Cinnamon cassia preparations and OHA in reducing fasting blood glucose level 
was not consistent. One trial showed a significant reduction in fasting blood glucose levels 
(B. Mang et al., 2006). However, two others reported no significant change with trials of 3 to 
4 months (S.M. Blevins et al., 2007; S. Suppapitiporn& N. Kanpaksi, 2006). There was no 
overall effect on HbA1c changes. Only one trial reported significant improvement in HbA1c 
level after 3 months (Standard mean difference (SMD) 0.12 g%; 95%CI -0.26 to 0.50) (P. 
Crawford, 2009). However, this change did not translate into an overall significant effect 
size. Further, three trials of 3 and 4 month durations reported no significance improvement 
in the HbA1c with this botanical intervention (S.M. Blevins et al., 2007; B. Mang et al., 2006; 
S. Suppapitiporn& N. Kanpaksi, 2006). Three trials of 3 and 4 months duration did not find 
any significant effect on the lipid levels (S.M. Blevins et al., 2007; B. Mang et al., 2006; S. 
Suppapitiporn& N. Kanpaksi, 2006).  
Adverse effect of hypersensitivity rash was reported in only one trial (P. Crawford, 2009). 
Comparison of these studies was difficult in view of different baseline biochemical 
characteristics (blood glucose, HbA1c, insulin, lipid level), weight, diet and concurent 
medications. 
There was no significant difference between Camelia sinesis extracts (catechin and theaflavin) 
with OHA and placebo in HbA1c (T. Mackenzie et al., 2007; T. Nagao et al., 2009) and 
fasting blood glucose levels (T. Nagao et al., 2009). Although there was a significant increase 
in the insulin level in the catechin-rich beverage group, the number of participants was too 
small (n=23) for further interpretation (T. Nagao et al., 2009). Adverse effects reported were 
profuse sweating and rash, which led to withdrawal from the study. 
Compared with placebo, combination Silybum marianum and OHA significantly reduced 
both the FBG and HbA1c levels in two trials of four month durations (H.F. Huseini et al., 
2006; S.A. Hussain, 2007). Even so, results of other parameters such as 2HPBG, BMI and 
lipid levels, were not consistent. No side-effects were reported. 
Compared with placebo, the fruits and seeds capsules preparation of Momordica charantia 
and OHA showed no statistically significant effect on reduction of fasting blood glucose and 
HbA1c levels (A.M. Dans et al., 2007). Similarly, when compared with placebo, the 
treatment also showed no statistically significant reduction in secondary outcome measures, 
total cholesterol levels or body mass index when compared to placebo.  However, the minor 
adverse effects of gastrointestinal discomfort led to discontinuation of treatment.   
Ingestion of tea prepared from Gynostemma pentaphyllum and OHA for 12 weeks showed a 
significant reduction in FBG, HbA1c and insulin resistance, compared with placebo and 
OHA (V.T. Huyen et al., 2010). There were no adverse effects reported. 
Intervention with Citrullus colocynthis and OHA in 25 patients for 2 months demonstrated 
significant reduction in both FBG and HbA1c levels , compared with patients taking placebo 
and OHA (H.F. Huseini et al., 2009). There were no significant changes in secondary 
outcome measures of lipid levels.  However, three patients reported mild diarrhoea at the 
beginning of the study. 
Patients on Trigonella foenum-graecum capsules and OHA for 12 weeks showed significant 
improvement glycaemic profile, FBG, 2HPBG and  HbA1c, as well as symptoms, compared 
with placebo (F.R. Lu et al., 2008). However, there were no significant secondary outcomes 
change of BMI, hepatic and renal functions. Adverse effects of abdominal discomforts and 
diarrhoea led to withdrawal from intervention.  
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Compared with placebo, intervention with Panax ginseng extract capsules and OHA, 
significantly improved glucose tolerance and insulin sensitivity in a double-blind, placebo-
controlled crossover randomised clinical trial (V. Vuksan et al., 2008). There were no 
significant changes in HbA1c as well as safety biochemical parameters of liver and kidneys. 
Adverse effects of hypoglycaemia was reported. In addition, there was a high number of 
dropouts (50%). This was attributed to conflicting approaches used in the management of 
T2DM in mainstream medical practice and traditional herbal practice in the country of the 
trial.  
Finally, Pinus maritima bark extract pill and OHA demonstrated significant reduction in 
FBG, HbA1c and LDL-cholesterol, compared with placebo and OHA (S. Zibadi et al., 2008). 
This was over a relatively short duration of 3 months. However, there was no 
documentation of adverse effects. 
2.3 Discussions  
2.3.1 Summary of main results 
Fifteen randomised trials were included in this review. The exclusion of 7 trials was due to 
treatment duration of less than six weeks or reported outcomes not relevant to this review. 
The included trials compared different botanical preparation with or without combinations 
with hypoglycaemic agents versus placebo. Not all the trials provided data on dietary and 
lifestyle modification in patients with type 2 diabetes mellitus. Majority of the trials 
measured surrogate primary outcomes, some evaluated symptoms or adverse events. Two 
trials failed to demonstrate any improvements in the blood glucose control in terms of 
normalisation, reduction of fasting blood glucose, reduction of 2HPBG responses and 
reduction of HbA1c. This is in contrast with the majority that demonstrated improvements 
in the surrogate primary outcomes.  
Only some trials examined secondary outcomes such as lipid levels or BMI. Safety 
biochemical parameters of the kidney and liver were examined in a limited number of trials. 
The low methodological quality and the general small sample size in these trials 
contributing to the low power of all the studies. Taken together with the limited number of 
the trials identified for individual botanical preparations, caution is needed in interpreting 
the findings of these trials. In all these studies, there were no statements on the health-
related quality of life, well-being, socioeconomic status or costs. 
Compared with placebo, six botanical preparations with oral hypoglycaemics, Cinnamon 
cassia, Citrullus Colocynthis, Silybum marianum, Gynostemma pentaphyllum, trigonella foenum-
graecum L and Pinus maritima seemed to have varying effects on blood glucose control. The 
hypoglycaemic agents used are sulphonylureas, metformin, thiazoledinediones, glinides, 
glitazones, acarbose or combination therapies. In addition to the conflicting findings of the 
four trials using preparations of Cinnamon cassia, the botanical preparations above with 
potential effects on glucose, warrant further trials.  
2.3.2 Applicability of evidence 
The fifteen trials available for this review were only a small fraction (less than 3%) of the 
vast resources of potential botanicals for T2DM. For the four trials using Cinnamon cassia 
intervention, the extracts were of derived from different techniques, dosages and sources. 
Moreover, the placebos used as control of three of these trials also varied. One trial did not 
elaborate on the contents (S. Suppapitiporn& N. Kanpaksi, 2006), while two others used 
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wheat flour and microcrystalline cellulose (S.M. Blevins et al., 2007; B. Mang et al., 2006).  
Another trial did not use any placebo as control (P. Crawford, 2009). In addition, the time 
point for assessment of the effect of intervention for the four trials was not uniform. This 
time point was 3 months for two trials (S.M. Blevins et al., 2007; S. Suppapitiporn& N. 
Kanpaksi, 2006)and 4 months for the other two(T. Mackenzie et al., 2007; B. Mang et al., 
2006). Thus, these methodological issues may affect the results. 
Even though there were two trials for each of the botanical, Camillia sinensis and Silybum 
marianum, different preparations were used. This means that none of the preparations of 
trials in this review were tested at least twice. Furthermore, many trials used the ‘double-
blind’design but few reported blinding of outcome assessors. This may predisposed to the 
possibility of performance and reporting bias (D. Moher et al., 1998; K.F. Schulz et al., 1995). 
2.3.3 Quality of evidence 
Since all the trials in this review did not meet one or more essential risk of bias criteria, these 
trials were assessed having high risk of bias. There was no trial with moderate or low risk of 
bias. When quality criteria in terms of minimisation of selection, performance, attrition, and 
detection biases are met, trial of low risk of bias is indicated. Similarly, categorization into 
moderate risk of bias required the quality criteria to be partially fulfilled. 
2.3.4 Safety of botanical preparations 
The botanical preparations evaluated in this review generally did not report severe adverse 
effects. Thus, the conclusion on the safety of using these botanicals in the management of 
diabetic patients cannot be made. Further, many of the adverse effects were not sufficiently 
reported. None of the reviews looked for the effects of ‘botanical-drug’ interaction. It is 
important that both the beneficial and harmful effects in clinical trials of human given equal 
attention. 
Previous reviews examined the use the different modalities of complementary and alternative 
medicine (R. Nahas& M. Moher, 2009) or the use herbs and dietary supplements (G.Y. Yeh et 
al., 2003). This review differs in the respect that we are focussed on the update of the clinical 
trials of botanical preparations for type 2 diabetes mellitus of the last five years. This included 
randomised controlled clinical trials comparing botanical preparation with placebo or 
hypoglycaemic drugs in type 2 diabetes mellitus of duration exceeding six weeks. Previous 
reviews included both randomised and non-randomised controlled trials with interventions 
consisting of herbs, dietary supplements as well as minerals (vanadium and chromium) in 
both types of diabetics and healthy individuals. However, we limited our focus to potential 
botanicals for T2DM. Furthermore, our search strategy has no restriction to language. This is 
important as many of the trials with botanicals may appear in the languages in the regions 
where the use of botanicals is common, particularly in Asia. Finally, stringent criteria for 
quality assessment were used in this review based on recommendations by several authors 
(A.R. Jadad et al., 1996; L.L. Kjaergard et al., 2001; K.F. Schulz et al., 1995).  
Current approaches to the use of botanical preparations differ with the type of medical 
practices. The expectation of mainstream medical practice is standardisation of extracts of 
botanicals extracts of predominantly specific parts of single plant (P. Talalay, 2001). This 
preparation is further investigated based on a set of criteria, which include preparation 
consistent with the description in the pharmacopoeia, chemical standardisation, biological 
assays, animal models, and clinical testing for the particular condition. In comparison, 
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traditional medical practices may include non-herbal or herbal modalities or combination 
(H.T. Debas et al., 2006). The focus may be on symptoms, well-being and customising for 
each individual patient based on the differentiation of the patients’ ’syndrome’ based on the 
particular traditional medicine practice philosophy. However, in many communities in 
Asia, the use of plural practices for management of type 2 diabetes is common (K.L. 
Tackett& M.C. Jones, 2009). Since there is evidence of the potential of botanicals contributing 
to management of T2DM, it is important to further understand their uses. The pleiotropic 
properties may have other benefits for these diabetics. Further insight may allow the use as 
possible expanding armamentarium of the glucose lowering therapeutic agents or 
complementing other aspects of treatment such as medical nutritional therapy. Improving 
the morale of the patients rather than creating conflict with the patient’s use of other 
approaches, is important to ensure continuity of treatment and ultimately control of disease.  
In summary, the selected studies in this review showed variability of treatment 
interventions, control interventions and generally small effect sizes. None of the 
preparations were tested twice. As a result, there is insufficient evidence for any reliable 
conclusion of the potential benefits or harmful effects of these botanicals for type 2 diabetes 
mellitus. 
2.3.5 Limitations 
This systematic review has several limitations. First, there are limited trials available for 
selection. This may be due to the fact that research of these botanicals is still in the early 
days or publication bias. With the included trials, methodological issues were predominant. 
The poor quality of randomisation and blinding may exaggerate effects of the interventions 
due to systematic errors (bias). Potential bias may also occur during selection of patients, 
administration of treatment, and assessment of outcomes. Therefore, these methodologically 
less rigorous trials may show inappropriately skewed larger significant intervention effects 
than trials with more rigors (M. Egger et al., 2003; L.L. Kjaergard et al., 2001).  
Small sample size of the trials leads to diminished power of the results. This may explain the 
absence of a statistically significant difference between botanical preparations used for 
interventions (E. Christensen, 2007; G. Piaggio& A.P. Pinol, 2001). In other words, the 
analyses from the size of these trials may not establish with confidence that two 
interventions have equivalent effects.  
All the selected trials reported end-of treatment responses, ranging from six weeks to four 
months. Important long-term responses beyond this period are not known. Finally, not all 
the trials provide information on ethnicity of the participants. The recruitment of patients 
was limited to the respective centre of study. In addition, all the preparations used in the 
intervention arms were tested only once, which made it impossible to pool data. Thus, the 
applicability of the results to other ethnic groups or populations is not known. 
3. Conclusion  
Some of the botanical preparations in this review may have beneficial effects on glycaemic 
glucose control in people with T2DM. However, at this point of time, we cannot recommend 
any for routine clinical use. All the trials had low methodological quality. The beneficial 
effects need to be confirmed by large rigorous randomised controlled trials of high-quality. 
In addition, the adverse effects also need to be further elucidated. Nevertheless, results from 
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ongoing studies may provide more information on the potential clinical use of Cinnamon 
cassia, Momordica charantia and Camellia sinesis (Table 2).   
3.1 Implications for future research 
Although preclinical and early clinical trials suggest that the botanicals in this review may 
contribute to the management of T2DM, a potential methodological problem is the issue of 
the quality of these botanical preparations. An example is the varying effect of C. cassia 
preparations from different sources on glycaemic control. Some of the differences may arise 
with the varying climates, conditions for growing, harvesting and processing  (U. Solimene 
et al., 2007). Different parts of the plant may have a different proportion of bioactive 
compounds present. This may add to the complexity of characterisation, production of 
reliable and consistently effective products. Therefore, there is a need to address the 
standardisation and the quality of the products used in clinic trials. 
 
Ref Study design Country Intervention 
 
Control 
(P. Crawford, 2011) DBRCT USA 
Cinnamon bark and 
Cinnulin PF dietary 
supplements 
metformin 
(A. Tsiami, 2009) DBRPCT UK Cinnamon capsules
Starch capsule 
placebo 
(R. Ridout et al., 
2007) 
DBRPCT Canada 
Cinnamonforce 
capsule 
Placebo 
(K. Khawaja, 2009) DBRPCT Pakistan 
Momordica 
charantia capsule 
Wheat flour 
placebo capsule 
(C.H. Hsu, 2007) DBRPCT Taiwan 
epigallocatechin 
gallate predominant 
green tea extract 
Green tea extract 
placebo 
Table 2. Ongoing clinical trials of botanical interventions for type 2 diabetes mellitus.   
The trials in this review did not examine the effect of the botanical interventions over a 
prolonged period (over 4 months). Thus, the effects on the micro and macro-complications 
well as other benefits in the patients with T2DM are not known. Moreover, with the 
different methodologies used, the presence of confounders, the varieties in the diet and the 
difficulty in recording dietary intake make it difficult to interpret the results. Furthermore, 
there is also the practicality of maintaining a ‘stable’ oral hypoglycaemic agents regime over 
a long period. Introduction of relevant clinically important outcome measures for long-term 
follow up may improve the quality of the trial. 
Design of future trials comparing such botanical interventions with established 
hypoglycaemic drugs should be based on ’equivalence principle’. In view of the findings of 
preclinical studies suggesting benefits beyond glycaemic control, when comparing these 
botanical interventions combined with one or more established oral hypoglycaemic agents, 
verifying these potential benefits is suggested. Particularly, for the middle-aged and older 
patients with T2DM, relevant outcome measures should include functional outcomes, 
quality of life, well-being, socioeconomic status and costs.  
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The quality of assessment of adverse events may be improved with a standardised format. 
Several components of selection bias that affect the quality of randomised controlled trials of 
this review required attention. This is the detailed reporting of the methods used to generate 
allocation sequence and allocation concealment. Adequate descriptions of withdrawal or 
drop-out during the trial and use of intention-to-treat analysis will also contribute to the 
quality of the trial.  
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